Compare GSK plc (GSK) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JPMorgan Ultra Short Income ETF — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while JPMorgan Ultra Short Income ETF trades at $50.29 (market cap $42.37B). The key difference: GSK plc is far larger — about 2.2× JPMorgan Ultra Short Income ETF's market cap, and GSK plc pays a 3.9% dividend while JPMorgan Ultra Short Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and JPMorgan Ultra Short Income ETF for 46 Days on average.
| GSK | JPST | |
|---|---|---|
Market Cap | $91.88B | $42.37B |
Volume | 7,730,529 | 7,889,185 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $50.78 |
52-Week Low | $43.24 | $50.22 |
Typical Hold Time | 93 Days | 46 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.27 with minimal daily movement (+0.04%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased holdings. The fund continues its regular $0.17 dividend payments, maintaining income distribution consistency.
JPST faces headwinds from rising interest rate environment while benefiting from demand for ultra-short duration strategies. The ETF's active management approach has shown recent underperformance versus peers, creating both opportunity for yield-seeking investors and risk from competitive pressure. Market volatility continues to drive flows into cash-alternative strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
